FDA has allowed Athenex Inc.’s Investigational New Drug application for the clinical investigation of PT01 (Pegtomarginase) for the treatment of patients with advanced malignancies.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
